CD8A and non-small cell lung carcinoma: However, low expression of both PD-L1 and CD8-positive (CD8+) tumor-infiltrating lymphocytes (TILs) in advanced EGFR-mutant NSCLC was reported to underlie the low overall response rate to PD1 inhibitors [12, 13].